47 results
8-K
EX-99.1
ALTS
ALT5 Sigma Corp
30 Aug 24
ALT5 Sigma Appoints Peter Tassiopoulos as Chief Executive Officer
1:47pm
talented team to drive innovation and deliver exceptional service to our customers."
Mr. Tassiopoulos's appointment comes at a time that sees ALT5 Sigma … innovative, actionable solutions intended to help end the opioid crisis. The Company is dedicated to funding resources toward innovation, technology
424B5
ALTS
ALT5 Sigma Corp
23 Aug 24
Prospectus supplement for primary offering
2:44pm
, actionable solutions intended to help end the opioid crisis. The Company is dedicated to funding resources toward innovation, technology, and education … , innovation in the development of therapeutic solutions has been largely absent. Since 2010, there have been 20 approvals by the FDA for the treatment
8-K
EX-99.1
ALTS
ALT5 Sigma Corp
17 Jul 24
Amendments to Articles of Incorporation or Bylaws
2:55pm
to funding resources toward innovation, technology, and education to find a key resolution to the national opioid epidemic, which is one of the deadliest
424B5
ALTS
ALT5 Sigma Corp
21 Jun 24
Prospectus supplement for primary offering
5:20pm
. Despite the magnitude of the pain problem, innovation in the development of therapeutic solutions has been largely absent. Since 2010, there have been 20 … by leveraging our understanding of pain biology to address the large and growing problem of pain. While innovation in medical sciences has led to exciting new
424B5
ALTS
ALT5 Sigma Corp
6 May 24
Prospectus supplement for primary offering
4:57pm
annually. Despite the magnitude of the pain problem, innovation in the development of therapeutic solutions has been largely absent. Since 2010 … therapies by leveraging our understanding of pain biology to address the large and growing problem of pain. While innovation in medical sciences has led
8-K
EX-99.1
wbhi0pbpqk7 2wvk
15 Mar 24
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
9:02am
8-K
EX-99.1
fiv0vjiu
23 Aug 23
JanOne Technologies Announces Registered Direct Offering Priced At-The-Market under Nasdaq Rules
4:33pm
8-K
EX-99.2
wzywy3cm85x05fg 8o38
23 Aug 23
JanOne Technologies Announces Registered Direct Offering Priced At-The-Market under Nasdaq Rules
4:33pm
424B5
vd8qygt09ieez j7cs
22 Aug 23
Prospectus supplement for primary offering
12:54pm
8-K
EX-99.1
mnojzgi m7w7qqjar
31 May 22
Entry into a Material Definitive Agreement
8:52am
8-K
EX-99.1
wp2vhb
22 Jul 21
JanOne Selects CPC Clinical Research as Trial Manager for Phase 2b Study of JAN101 for Peripheral Artery Disease Patients
9:46am
8-K
EX-99.1
n69i3j lwh55egwkp
23 Jun 21
Company Fully Prepared to Commence Phase 2b Trials of JAN101 for Peripheral Artery Disease (PAD) as Soon as New Protocol is Approved by the FDA
10:14am
8-K
EX-99.1
g2ohy9zw4zcyy o3s1wg
22 Jun 21
JanOne Selects Regulatory Partner for Phase 2b Trial as Investigational Plan is Prepared for FDA Filing
9:46am
8-K
EX-99.1
3ods65z70g30m9t
15 Jun 21
JanOne Appoints Internationally Renowned Expert on Addiction Nicholas Goeders, Ph.D. to Scientific Advisory Board
10:16am
8-K
EX-99.1
vr25y4
8 Jun 21
Other Events
9:45am